In bid to ex­tend cash run­way, Cara to lay off work­ers, dis­con­tin­ue PhI­II pro­gram in chron­ic kid­ney dis­ease

Cara Ther­a­peu­tics is cut­ting its work­force by near­ly 50% and end­ing a Phase III pro­gram in­ves­ti­gat­ing an oral ver­sion of its opi­oid pep­tide in pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.